Hematopoietic Cell TransplantMT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Sponsor:

Masonic Cancer Center, University of Minnesota

Code:

NCT06412497

Conditions

Severe Aplastic Anemia

Acquired Amegakaryocytic Thrombocytopenia

Acquired Pure Red Cell Aplasia

Paroxysmal Nocturnal Hemoglobinuria

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

Rituximab

Rabbit ATG

Cyclophosphamide

Fludarabine

Total Body Irradiation

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-24. This information was provided to ClinicalTrials.gov by Masonic Cancer Center, University of Minnesota on 2026-06-03.